Purastat® vs Standard Therapy for Haemostasis During Endoscopic Submucosal Dissection
Randomised Controlled Trial Comparing Purastat® to Standard Therapy for Haemostasis Control During Endoscopic Submucosal Dissection
1 other identifier
interventional
101
1 country
1
Brief Summary
Endoscopic submucosal dissection (ESD) is an endoscopic resection technique used to treat superficial neoplasia in the gastrointestinal tract. Bleeding is a commonly encountered problem during submucosal dissection and is usually managed with electrocautery. However, this does carry a risk of deep thermal injury and perforation. PuraStat® is a novel extracellular scaffold matrix of amino acids that forms a transparent adherent barrier when applied to a bleeding point. The aim of this trial is to study the use of PuraStat® in reducing the need for thermal haemostasis during ESD.
Trial Health
Trial Health Score
Automated assessment based on enrollment pace, timeline, and geographic reach
participants targeted
Target at P50-P75 for not_applicable
Started May 2016
Typical duration for not_applicable
1 active site
Health score is calculated from publicly available data and should be used for screening purposes only.
Trial Relationships
Click on a node to explore related trials.
Study Timeline
Key milestones and dates
Study Start
First participant enrolled
May 4, 2016
CompletedFirst Submitted
Initial submission to the registry
June 29, 2016
CompletedFirst Posted
Study publicly available on registry
July 14, 2016
CompletedPrimary Completion
Last participant's last visit for primary outcome
April 12, 2018
CompletedStudy Completion
Last participant's last visit for all outcomes
May 18, 2018
CompletedJune 26, 2018
June 1, 2018
1.9 years
June 29, 2016
June 21, 2018
Conditions
Keywords
Outcome Measures
Primary Outcomes (1)
The number of times intraprocedural heat therapy is used to achieve haemostasis in ESD in both the PuraStat® and control arms of the study
Measured during the ESD procedure
Secondary Outcomes (4)
The length of the procedure in the PuraStat® and control arm of the study
Measured during the ESD procedure
The number of patients with delayed bleeding (bleeding within 28 days) in both the PuraStat® and control arm of the study
28 days
Wound healing in the PuraStat® and control arm at 6 weeks post ESD
6 weeks
Number of adverse events in the PuraStat® and control arm of the study
14 months
Study Arms (2)
PuraStat®
EXPERIMENTALInterventional arm: PuraStat® applied through a catheter delivery system via the endoscope is used to stop bleeding during ESD.
Standard Electrocautery
OTHERControl arm where standard electrocautery delivered via the endoscopic knife tip or coag grasper is used to achieve haemostasis during ESD
Interventions
PuraStat® gel is applied through a safe catheter delivery system (via endoscope) over the bleeding point
Electrocautery (coagulation current) to stop bleeding during ESD
Eligibility Criteria
You may qualify if:
- Male or Female, aged 18 years or above.
- An ESD is attempted for clinical indications approved by MDT.
- Oesophageal or colonic lesion 2-5cm in size
- Participant is willing and able to give informed consent for participation in the study
You may not qualify if:
- Known coagulopathy likely to affect risk of bleeding
- Submucosal tumour
- Anticoagulation or anti-platelet therapy (apart from single modality aspirin or clopidogrel) which cannot be stopped for clinical reasons
- Patient preference
Contact the study team to confirm eligibility.
Sponsors & Collaborators
Study Sites (1)
Portsmputh Hospitals NHS Trust
Portsmouth, PO6 3LY, United Kingdom
MeSH Terms
Conditions
Interventions
Condition Hierarchy (Ancestors)
Intervention Hierarchy (Ancestors)
Study Officials
- PRINCIPAL INVESTIGATOR
Pradeep Bhandari, MBBS, MD
Portsmouth Hospitals NHS Trust
Study Design
- Study Type
- interventional
- Phase
- not applicable
- Allocation
- RANDOMIZED
- Masking
- SINGLE
- Who Masked
- PARTICIPANT
- Purpose
- TREATMENT
- Intervention Model
- PARALLEL
- Sponsor Type
- OTHER GOV
- Responsible Party
- SPONSOR
Study Record Dates
First Submitted
June 29, 2016
First Posted
July 14, 2016
Study Start
May 4, 2016
Primary Completion
April 12, 2018
Study Completion
May 18, 2018
Last Updated
June 26, 2018
Record last verified: 2018-06
Data Sharing
- IPD Sharing
- Will share